Nanosensors are miniature devices engineered at the nanoscale to detect physical, chemical, or biological changes in a living system. They consist of two core components:
- Biorecognition Element: It can be an antibody, aptamer, or enzyme.
- Transducer: It converts the molecular binding event into a measurable signal, whether electrical, optical, or mechanical.1
Their defining advantage lies in their size. At the nanoscale, materials exhibit a dramatically higher surface-to-volume ratio, which amplifies interactions with target molecules and produces signals that larger devices simply cannot generate. This physical property makes nanosensors capable of detecting biomarkers at concentrations in the femtomolar or even attomolar range.1
How do They Work?
Nanosensors function through a process called signal transduction. When a target biomarker, such as a protein, nucleic acid, or small molecule, binds to the sensor's recognition element, it triggers a measurable physicochemical change. Depending on the sensor design, this change can manifest as a shift in electrical conductance, a change in fluorescence intensity, or an alteration in surface plasmon resonance.1
Common nanomaterials used in these platforms include gold nanoparticles, graphene, carbon nanotubes, and quantum dots. Gold and silver nanoparticles are particularly valuable because of their strong surface-enhanced Raman scattering (SERS) properties, which amplify the optical signal of target molecules by factors exceeding 106. Quantum dots offer tunable fluorescence and photostability, making them well-suited for multiplexed detection where several biomarkers need to be identified at once.1
Nanosensors in Cancer Detection
Cancer biomarkers circulate in blood, urine, and saliva long before tumors become visible on a scan. SERS-based nanosensors targeting tumor markers have achieved sensitivity greater than 95% and specificity greater than 90% in early-stage cancer cohorts.1
Similarly, quantum dot bioconjugates, formed by attaching antibodies to luminescent semiconductor nanocrystals, have demonstrated a detection limit of 1 ng/mL for prostate-specific antigen (PSA) with an imaging accuracy of 93%. Atomic force microscopy (AFM) cantilevers functionalized for BRAF mutation detection, a key marker in melanoma, delivered 92% sensitivity with a response time under five minutes, offering a label-free path to rapid molecular diagnosis.1,2
Graphene-based electrochemical sensors have also been adapted for detecting cancer-related proteins directly in blood samples. Recent advances in nanomaterial positioning within sensor electrodes and bioreceptors have made it possible to diagnose cancer at biomarker concentrations that previously required amplification steps, reducing both time and sample volume.2
Detecting Cardiovascular Disease Earlier
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, and many patients experience cardiac events with no prior warning. Nanoparticle-based biosensors have been designed to target specific CVD biomarkers, including cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), and Galectin-3, all of which are released into the bloodstream during cardiac stress.3
Optical and electrochemical nanosensors incorporating inorganic nanoparticles have demonstrated reliable detection of these markers, with nanomaterials improving the immobilization of capture molecules, such as antibodies and aptamers, on sensor surfaces due to their large surface area.
Recent work on covalent organic frameworks (COFs), metal-organic frameworks (MOFs), MXenes, and two-dimensional nanostructures has further enhanced sensitivity and selectivity in complex clinical samples such as serum and plasma.3,4
Neurodegenerative Disease Biomarkers
Alzheimer's and Parkinson's diseases progress silently for years before cognitive or motor symptoms become apparent. Nanobiosensors designed for amyloid-beta and tau protein detection in cerebrospinal fluid, blood, and saliva have shown detection limits as low as 10 pg/mL, a significant improvement over conventional ELISA methods, which typically detect at 10 to 100 ng/mL.5
Electrochemical nanobiosensors using gold nanoparticles, carbon nanotubes, and graphene improve electron transfer at the electrode surface and can detect phosphorylated tau proteins at ultra-low concentrations. For Parkinson's disease, a gold nanowire and exfoliated graphene oxide-modified electrode has been used to detect miR-195, a circulating microRNA biomarker, through differential pulse voltammetry, demonstrating that nanosensors can read genetic signals from minimally invasive blood draws rather than lumbar punctures.5
Infectious Disease and Point-of-Care Testing
Speed determines outcomes in infectious disease management. A 3D plasmonic nanoantenna-based immunosensor for Ebola virus antigen detection achieved a limit of detection of 220 fg/mL in human plasma, with a sensitivity of 95.8%, making it viable for outbreak settings where laboratory infrastructure is unavailable.1
Download the PDF of this page here
Nanosensor-integrated lateral flow assays, surface acoustic wave biosensors, and CRISPR-Cas-based platforms bring these detection capabilities into point-of-care formats. These platforms deliver results in under 10 minutes, do not require trained personnel or cold-chain equipment, and operate directly on extracted patient samples, making them practical in resource-limited settings.6,7
Wearable and Continuous Monitoring
Nanosensors have moved beyond single-use diagnostic tests into wearable platforms that track health in real time. Graphene-based glucose nanosensors for diabetes management have achieved detection limits as low as 0.0054 mg/dL and linear ranges from 0.18 to 900.78 mg/dL, far exceeding the analytical precision of commercial continuous glucose monitors.1
Platforms coated with Nafion and chitosan maintain signal fidelity in serum for up to 48 hours while resisting biofouling, a key challenge for implantable or skin-worn devices. Breath nanosensors for volatile organic compound (VOC) detection have demonstrated detection limits of 0.5 parts per billion and 92% accuracy in lung cancer screening, pointing toward a future in which a simple breath test replaces imaging-based screening protocols.1
Challenges in Clinical Translation
Despite their performance in laboratory settings, nanosensors face real barriers before entering routine clinical use. Reproducible manufacturing at scale remains difficult, as small variations in nanoparticle size or surface chemistry can substantially affect sensor performance. Long-term biocompatibility, particularly for implantable devices, requires extensive validation before regulatory agencies will approve their use in humans.1,5
Standardization is another pressing challenge. Without agreed-upon benchmarks for sensitivity, selectivity, and limit of detection across disease categories, comparing platforms from different research groups or manufacturers is difficult. Addressing these gaps through interdisciplinary collaboration between materials scientists, clinicians, and regulatory experts will determine how quickly nanosensor technology moves from the research bench into hospitals and homes.1
References and Further Reading
- Ma, T. et al. (2025). Nano-Engineered Sensor Systems for Disease Diagnostics: Advances in Smart Healthcare Applications. Biosensors, 15(12), 777. DOI:10.3390/bios15120777. https://www.mdpi.com/2079-6374/15/12/777
- Khandelwal, D. et al. (2024). Leveraging Nanomaterials for Ultrasensitive Biosensors in Early Cancer Detection: A Review. Journal of Materials Chemistry B. DOI:10.1039/d4tb02107j. https://pubs.rsc.org/de-at/content/articlelanding/2025/tb/d4tb02107j
- Saadh, M. J. et al. (2025). Nanoparticle biosensors for cardiovascular disease detection. Clinica Chimica Acta, 567, 120094. DOI:10.1016/j.cca.2024.120094. https://www.sciencedirect.com/science/article/abs/pii/S0009898124023477
- Nangare, S. N., & Jadhav, N. R. (2025). Nanoengineered biosensors: Advancing coronary artery disease diagnosis with cutting-edge nanomaterials. Measurement, 256, 118188. DOI:10.1016/j.measurement.2025.118188. https://www.sciencedirect.com/science/article/abs/pii/S0263224125015477
- Yadav, S. et al. (2025). Nanobiosensors in neurodegenerative disease diagnosis: A promising pathway for early detection. Digital Health, 11, 20552076251342457. DOI:10.1177/20552076251342457. https://journals.sagepub.com/doi/10.1177/20552076251342457
- Secchi, V. et al. (2025). Advanced techniques and nanotechnologies for point-of-care testing. Frontiers in Nanotechnology, 6, 1465429. DOI:10.3389/fnano.2024.1465429. https://www.frontiersin.org/journals/nanotechnology/articles/10.3389/fnano.2024.1465429/full
- Bruno, A. et al. (2024). Advancements in nanosensors for detecting pathogens in healthcare environments. Environmental Science: Nano. DOI:10.1039/d4en00381k. https://pubs.rsc.org/en/content/articlehtml/2024/en/d4en00381k
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.